



# Financial Tear Sheet

## Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe **EG-1962**, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. A single dose of EG-1962 delivers a high concentration of nimodipine, the current standard of care, directly to the brain with sustained drug exposure over 21 days.

In April 2015, we completed enrollment in a Phase 1/2 trial of **EG-1962** in North America, which we refer to as our NEWTON trial, and met our primary and secondary endpoints of safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics. We intend to initiate our Phase 3 program in the first half of 2016.

Our second product candidate, EG-1964, is being developed as a potential prophylactic treatment in the management of chronic subdural hematoma, or cSDH, to prevent recurrent bleeding on the surface of the brain. Recurrent bleeding occurs in up to 30% of cSDH patients, requires repeat neurosurgical intervention and is associated with risks of serious complications, including death. There are currently no approved therapeutic treatments that reduce the risk of recurrent bleeding after cSDH. Following discussions with the FDA, we intend to submit an IND for EG-1964 in 2016.


## Stock Performance

## Primary IR Contact

Gregory Gin

**E-mail:**

[ir@edgetherapeutics.com](mailto:ir@edgetherapeutics.com)



**EDGE (Common Stock)**

Exchange NASDAQ GS (US Dollar)

Financial Status Indicator C

Price **\$1.10**

Change (%) 0.00 (0.00%)

Volume 121,540

52 Week Low \$0.84

Market Cap \$34,370,854

Rolling EPS -2.36

PE Ratio 0

Shares Outstanding 31,246,231

Data as of June 20, 2018 4:00 p.m. ET

## Recent Press Releases & Upcoming Events

May 1, 2018

Edge Therapeutics Reports First Quarter 2018 Financial Results

April 30, 2018

Edge Therapeutics Announces Review of Strategic Alternatives

March 28, 2018

Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

There are currently no events scheduled.

## SEC Filings

<b>Filing Date</b>	<b>Form</b>
June 20, 2018	4
June 20, 2018	8-K/A
June 20, 2018	4
June 20, 2018	4

## Corporate Governance

Brian Leuthner	President and CEO
R. Loch Macdonald, M.D., Ph.D	Chief Scientific Officer
Andrew Einhorn	Chief Financial Officer
Herbert J. Faleck, D.O.	Chief Medical Officer
Bert Marchio	Chief Accounting and Operations Officer
Alpaslan Yaman, Ph.D.	Vice President, Operations and Manufacturing
W. Bradford Middlekauff	Senior Vice President and General Counsel

Data provided by Nasdaq. Minimum 15 minutes delayed.